


SWIXX BIOPHARMA FORMALLY CLOSES THE DEAL WITH BIOPAS, EXPANDING TO LATIN AMERICA

- *Acquisition approved by relevant regulatory authorities and is now completed*
- *The combination with Biopas, which was [announced preliminarily on May 22nd, 2024](#), extends & transforms Swixx Biopharma's geographical footprint creating a compelling, single-stop, multi-continent partner for biopharma companies*

Baar, Switzerland, July 4th, 2024 – Swixx Biopharma is pleased to announce the successful closing of its acquisition and combination with Biopas, marking a significant expansion into the Latin American market. This strategic move underscores Swixx Biopharma's commitment to broadening its geographical footprint and enhancing its service offerings.

 **Jean-Michel Lespinasse, CEO of Swixx BioPharma** commented: "We are thrilled to welcome Biopas into the Swixx BioPharma family. Building on our matching cultures and vision, the combined entity firmly moves forward, leveraging its global strengths and capabilities to better serve the needs of patients and healthcare professionals." He continued: "This strategic transaction is a testament to the hard work and dedication of our teams, as well as of the outstanding support from our legal and financial partners, who we warmly thank. "

Transaction Support

Walder Wyss acted as lead legal counsel for Swixx BioPharma, supported by Cuatrecasas and Arias Fábrega and Fábrega (ARIFA Panama). DLA Piper France and EY Czech coordinated the due diligence process with their affiliates and partners. BGPartner and Advestra AG provided legal advice on the transaction financing process. UBS, Credit Suisse, Citibank, and BNP Paribas supported the transaction financing. Swixx BioPharma extends our appreciation to all teams involved in facilitating the acquisition.

BTG Pactual and Martinez Quintero were the lead advisors for Biopas. Homburger and RBC Panamá supported Biopas in the transaction process. Biopas expresses gratitude to the professionals from those companies and all others that supported the acquisition process.

About Swixx BioPharma

Swixx BioPharma, now incorporating Biopas, is one of the fastest-growing, largest, intercontinental commercial platforms for the biopharmaceutical industry. Swixx operates subsidiaries across Central and Eastern Europe, Greece, Russia, several Eurasian countries, the Middle East, and via Biopas, a Swixx BioPharma company, in almost 20 Latin American countries. Swixx BioPharma Group has over 1,600 employees and sales likely to exceed a billion Euros in 2024. The company has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx BioPharma, please visit: www.swixxbiopharma.com.



Swixx BioPharma Investor and partner inquiries:

Jean-Michel Lespinasse, CEO
bd.info@swixxbiopharma.com

Stuart Swanson, Head of Corporate Development
bd.info@swixxbiopharma.com

Swixx BioPharma media inquiries:

Vedrana Sokac Brataljenovic, Public Affairs Director
vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086

